Adheron Therapeutics

Adheron is a biotechnology company focused on leveraging pioneering technology that disrupts cell adhesion to treat a variety of diseases.

Adheron Therapeutics was established in 2006 as Synovex Corporation. The company’s therapeutic program is based on pioneering work done in the laboratory of Dr. Michael Brenner at Brigham and Women’s Hospital and Harvard Medical School. Dr. Brenner discovered that Cadherin-11 (Cad-11) acts as an “adhesive’ between cells and hanges in these Cad-11 interactions can induce the cells to produce many proteins that influence the cellular environment positively or adversely. Based on this discovery, Adheron is developing a best-in-class antibody tackling a variety of diseases by disrupting the adhesion of cells.